AdvanCell

AdvanCell is a clinical-stage radiopharmaceutical company that develops targeted alpha therapies for cancer.

Health and bio Manufacturing and industrial

Latest funding

$315M Series B+ · July 15, 2026

Led by Ally Bridge Group · Source: fundraisingfox.com

Total raised: $439.5M across 3 sourced rounds

All 3 rounds ↓

Website: advancell.com.au.

LinkedIn: advancell.

Categories: Health and bio Manufacturing and industrial.

Sectors: Biotechnology, Clinical Trials, Oncology, Pharmaceutical.

Stage: Series B+.

Based in: Sydney, Australia.

Founded: 2019.

Total raised: $439.5M in 3 sourced rounds.

Last round: Jul 15, 2026 · 123 days ago.

Headcount: 101–250 employees.

On Recent Funding since: Sep 29, 2026.

Signals

Website registeredFeb 17, 2021 (5 years old)

About AdvanCell

It creates therapies based on Lead-212 and other alpha-emitting isotopes. AdvanCell also develops manufacturing technologies and supply capabilities for these therapies. Its customers are patients with untreatable cancers.

TIMELINE · MONEY RAISED

AdvanCell | 553 days from website to first raise on record

Raised $440M in 3 sourced rounds·1 signal before the first raise

Money raised, round by round (amounts linked to their source). Pins are dated signals; hover the icons for dates.

Funding rounds

Date	Round	Amount	Lead	Source
Jul 15, 2026	Series B+	$315M	AAlly Bridge Group	fundraisingfox.com
Feb 3, 2025	Series B+	$112M	AAbingworth	advancell.com.au
Aug 24, 2022	Series B+	$12.5M	MMorningside	advancell.com.au

Timeline

February 17, 2021
Website created

Founders and team

AA
Andrew Adamovich Founder & Managing Director, Australia

LinkedIn · source: advancell.com.au
FG
François Gaudet Chief Scientific Officer
JK
Justyna Kelly Chief Technology Officer
PL
Philina Lee Chief Executive Officer

Investors

Companies like AdvanCell

AAlpha-9 Oncology$175M Series B+ · Oct 2024
SStorm Therapeutics$56M Series B+ · Apr 2026
SSkopos Bio$12M Seed · Sep 2026
AAsta Bio
VVaderis Therapeutics$152M Series B+ · Aug 2026
EEngrail Therapeutics$157M Series B+ · Mar 2024

Other companies backed by Ally Bridge Group

CCMR Surgical$400M Series B+ · Oct 2026
EEpicrispr Biotechnologies$90M Series B+ · Aug 2026
VVida Health$4M Series A · Nov 2025
CCardiac Dimensions$53M Series B+ · Mar 2025
TTranscarent$126M Series B+ · May 2024
AAlzheon$100M Series B+ · Apr 2022

Ally Bridge Group portfolio →

Sources and API

Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/advancell (get a free API key).